Atiprimod: Phase I/IIa started

CLSP began an open-label, dose-escalation U.S. Phase I/IIa trial in about 42 patients. CLSP received exclusive worldwide rights to the compound from AnorMed Inc. (TSE:AOM, Vancouver, B.C.). ...